Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773942 | 0.93 | CNR2 (0.49) | MEN1KMT2AHRH3CNR2TSHR | |
| SCHEMBL3773905 | 0.87 | HRH3 (0.45) | MEN1KMT2AHRH3TSHRSMN1; SMN2 | |
| SCHEMBL3767918 | 0.87 | HRH3 (0.47) | MEN1KMT2AHRH3TSHRSMN1; SMN2 | |
| SCHEMBL3769368 | 0.86 | DPP4 (0.42) | MEN1KMT2AHRH3CNR2CNR1 | |
| SCHEMBL3770099 | 0.86 | HRH3 (0.42) | MEN1KMT2AHRH3TSHRSMN1; SMN2 | |
| SCHEMBL3774007 | 0.85 | CNR2 (0.54) | MEN1KMT2AHRH3CNR2CNR1 | |
| SCHEMBL3774634 | 0.85 | KMT2A (0.49) | MEN1KMT2AHRH3TSHRSMN1; SMN2 | |
| SCHEMBL3767885 | 0.84 | HRH3 (0.43) | MEN1KMT2AHRH3TSHRSMN1; SMN2 | |
| SCHEMBL3761224 | 0.84 | PANK3 (0.42) | MEN1KMT2AHRH3TSHRSMN1; SMN2 | |
| SCHEMBL3767969 | 0.84 | CYP11B2 (0.44) | HRH3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | MEN1 3270/4885KMT2A 242/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.